PTGES and hepatocellular carcinoma: 2,5-Dimethylcelecoxib (DMC) is a targeted inhibitor of mPGES-1, a key enzyme in the PGE2 synthesis pathway of inflammatory mediators and the inhibition of growth of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).